<p>Frontotemporal lobar degeneration (FTLD) is one of the leading causes of dementia in individuals younger than 65 years. The FTLD symptoms of most patients are not yet explained by mutations in the known FTLD genes (<a href="https://www.ncbi.nlm.nih.gov/gene/203228">C9orf72</a>, <a href="https://www.ncbi.nlm.nih.gov/gene/2896">GRN</a>, <a href="https://www.ncbi.nlm.nih.gov/gene/4137">MAPT</a>). Identifying genetic risk associated with the disease is key for developing disease models and new therapeutic avenues. We performed short-read whole-genome sequencing (WGS) on 19 neuropathologically normal individuals and 560 patients with FTLD, including 171 pathologically confirmed FTLD patients, 352 clinically diagnosed FTLD patients, and 37 autosomal dominant FTLD patients. Pathologically confirmed FTLD patients include FTLD with TDP43 inclusions (FTLD-TDP) and FTLD with FUS inclusions (FTLD-FUS), autosomal dominant FTLD patients include GRN (FTLD-TDP GRN) and C9ORF72 (FTLD-TDP C9ORF72) mutation carriers, clinically diagnosed patients include behavioral variant of frontotemporal dementia (bvFTD), frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS), frontotemporal dementia with corticobasal syndrome (FTD-CBS), semantic variant of primary progressive aphasia (svPPA), and non-fluent variant of primary progressive aphasia (nfvPPA). </p>

Whole Genome Sequencing Consortium on Frontotemporal Dementia With    Underlying TDP-43 Pathology

Frontotemporal Lobar Degeneration study with SNP/CNV Genotypes (NGS), WGS data on dbGaP (577 participants)